This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| Ac-SDKP | KPV | |
|---|---|---|
| Highest evidence tier on the page | E3 Early human evidence Small, open-label, uncontrolled, case series, or a registered trial with no published results. | E4 Preclinical only Animal or in vitro work. Not demonstrated in humans. |
| Regulatory status | Not FDA-approved; not known to be in active clinical development; research/mechanistic-study compound | Not approved for human use |
| Research area | Tissue repair and recovery | Sexual health and melanocortin, Tissue repair and recovery |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C20H33N5O9 | C16H30N4O4 |
| Molar mass | Approximately 487.51 g/mol | 342.44 g/mol |
| CAS number | 120081-14-3 | 67727-97-3 |
| Registered trials on this site | None linked yet | None linked yet |
| What is not known | No completed human clinical trial administering Ac-SDKP itself (at any dose or route) was identified in the sources reviewed for this entry. A 2006 published review (Cavasin, PMID 17083265) explicitly states no clinical trial data existed supporting its use for cardiac healing at that time,... | Whether KPV does anything in a human being. No trial has asked. Beyond that: no human pharmacokinetics or bioavailability by any route, no half-life, no toxicology package, and no chronic-use data in any species. No published binding affinity for any melanocortin receptor. No drug-interaction data,... |
Full pages: Ac-SDKP and KPV. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
